{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:21:32Z","timestamp":1782476492161,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107269","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:30:02Z","timestamp":1779676202000},"page":"107269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Seronegative demyelinating disease within the neuromyelitis optica\/MOG antibody-associated disease spectrum following nivolumab and ipilimumab: A case report and literature review"],"prefix":"10.1016","volume":"111","author":[{"given":"Apostolos","family":"Spiliopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristea","family":"Leventouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Sagona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Zampakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinovia","family":"Kefalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Chroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107269_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.msard.2026.107269_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200382","article-title":"Progressive myelitis in a 63-year-old woman","volume":"12","author":"DiMauro","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2026.107269_bib0008","article-title":"Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol.: Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2026.107269_bib0002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107269_bib0003","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-022-02987-6","article-title":"A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study","volume":"22","author":"Hirano","year":"2022","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.107269_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.806501","article-title":"Case report: neuromyelitis optica after treatment of uveal melanoma with nivolumab and ipilimumab","volume":"12","author":"Khimani","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.msard.2026.107269_bib23","doi-asserted-by":"crossref","first-page":"107094","DOI":"10.1016\/j.msard.2026.107094","article-title":"The case for seronegative MOG antibody syndrome (SMOGAS)","volume":"108","author":"Levy","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107269_bib0005","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-025-08710-w","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma","volume":"47","author":"Li","year":"2026","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107269_bib0006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.0000000000200055","article-title":"MOG-IgG\u2013Associated demyelination induced by Pembrolizumab treatment in a patient with malignant melanoma","volume":"98","author":"Liu","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107269_bib0007","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.neurol.2024.08.004","article-title":"What\u2019s new in NMOSD and MOGAD?","volume":"180","author":"Marignier","year":"2024","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107269_bib0021","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.msard.2026.107269_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102451","article-title":"Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events","volume":"46","author":"Nasralla","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107269_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2025.109120","article-title":"Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab","volume":"257","author":"Oelbrandt","year":"2025","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.msard.2026.107269_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107269_bib0012","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s10072-023-07252-3","article-title":"Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma","volume":"45","author":"Prieto","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107269_bib0014","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2026.107269_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101447","article-title":"Neuromyelitis optica spectrum disorder after treatment with pembrolizumab","volume":"37","author":"Shimada","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107269_bib0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10637-021-01154-x","article-title":"Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer","volume":"40","author":"Wang","year":"2022","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.msard.2026.107269_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2588020","article-title":"Management of MOG antibody-associated disease by pembrolizumab and radiation myelopathy in an elderly patient: a case report and literature review","volume":"21","author":"Wang","year":"2025","journal-title":"Hum. Vaccin. ImmunOther"},{"key":"10.1016\/j.msard.2026.107269_bib0018","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s00415-021-10913-y","article-title":"Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab","volume":"269","author":"Weiss","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107269_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107269_bib0020","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107269_bib0022","first-page":"58","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"18","author":"\u017divkovi\u0107","year":"2022","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:43:03Z","timestamp":1780976583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S2211034826003056"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107269","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seronegative demyelinating disease within the neuromyelitis optica\/MOG antibody-associated disease spectrum following nivolumab and ipilimumab: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107269"}}